Published in the journal Nature Immunology, this paper provides an important perspective on the role that B cells play in the immune response to cancer that will help the development of improved therapies to treat these diseases.
Ralph Minter, Ph.D. presented “Resilience-Associated CD33 Antibody ATLX-1088, A Potent Stimulator of Microglial Phagocytosis” at AD/PD 2024, the International Conference on Alzheimer’s and Parkinson’s Diseases held 6th March 2024.
Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop.
Michelle Sidor and Iosif Pediaditakis presented the following posters: ‘Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology’ and ‘Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues’.
Alchemab’s Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer’s disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.
Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023.
Learn more about B cell immune repertoires from Jane Osbourn, Alchemab CSO & co-founder, presenting at the Genomics England Research Summit
Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity.